Table 1 SNOT-22 domain outcomes.

From: Impact of dupilumab on SNOT-22 domain and individual item scores in chronic rhinosinusitis with nasal polyps

SNOT-22 domain

Baseline

6-month follow-up

Change [95%CI]

p-value

Effect size d

Nasal domain

24.4 ± 7.8

11.1 ± 7.9

13.3

[11.3, 15.2]

< 0.001

1.4

Otologic/facial pain domain

5.3 ± 4.6

1.9 ± 3.1

3.4

[2.4, 4.3]

< 0.001

0.7

Sleep domain

19.8 ± 10.4

9.5 ± 8.8

10.3

[8.3, 12.2]

< 0.001

1.1

Emotional domain

3.5 ± 2.7

1.4 ± 1.7

2.5

[1.6, 2.6]

< 0.001

0.8

  1. SNOT-22: Sinunasal Outcome Test 22. Variables are presented as means ± standard deviations and 95% confidence interval (CI).
Back to article page